Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B5775

Supelco

Bendroflumethiazide

analytical standard

Synonym(s):

3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H14F3N3O4S2
CAS Number:
73-48-3
Molecular Weight:
421.41
EC Number:
200-800-1
MDL number:
MFCD00078963
UNSPSC Code:
41116107
PubChem Substance ID:
329773267
NACRES:
NA.24

grade

analytical standard

Quality Level

200

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

SMILES string

NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F

InChI

1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)

InChI key

HDWIHXWEUNVBIY-UHFFFAOYSA-N

Gene Information

human ... SLC12A3(6559)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Bendroflumethiazide belongs to the class of thiazide diuretics, widely used in enhancing diuresis. It is also used as an effective antihypertensive agent and in the treatment of edema caused by cardiac/renal failure and myocardial infarction. Its mode of action involves increasing the urine flow and the net renal excretion of both sodium and water.

Application

Bendroflumethiazide may be used as an analytical reference standard for the quantification of the analyte in pharmaceutical formulations using different chromatography techniques.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000293837
079F1025V
079F1025
079F1025

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David S Wald et al.
Journal of evaluation in clinical practice, 18(3), 612-615 (2011-02-01)
A combination of medications that simultaneously reduce several cardiovascular risk factors in people above a specified age, without selection based on risk factor measurement, has been proposed as a simple strategy for reducing the risk of cardiovascular disease and shown
Isla S Mackenzie et al.
Hypertension (Dallas, Tex. : 1979), 54(2), 409-413 (2009-06-03)
Isolated systolic hypertension is an important risk factor for cardiovascular disease and results primarily from elastic artery stiffening. Although various drug therapies are used to lower peripheral blood pressure (BP) in patients with isolated systolic hypertension, the effects of the
The
Current Cardiovascular Drugs, 9(4), 1069-1076 (2005)
Analysis of diuretic doping agents by HPLC screening and GC?MSD confirmation
Tsai Y-F, et al.
Journal of Pharmaceutical and Biomedical Analysis, 9(10-12), 1069-1076 (1991)
D Tricarico et al.
British journal of pharmacology, 154(1), 183-190 (2008-03-18)
Acetazolamide and dichlorphenamide are carbonic anhydrase (CA) inhibitors effective in the clinical condition of hypokalemic periodic paralysis (hypoPP). Whether these drugs prevent vacuolar myopathy, which is a pathogenic factor in hypoPP, is unknown. The effects of these drugs on the
View All Related Papers

Chromatograms

application for HPLC

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service